Anti-CD20 therapies and pregnancy in neuroimmunologic disorders
A cohort study from Germany
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 2, 2020
- Accepted in final form October 6, 2020
- First Published December 17, 2020.
Author Disclosures
- Tania Kümpfel, MD*,
- Sandra Thiel, PhD*,
- Ingrid Meinl, MD,
- Andrea I. Ciplea, PhD,
- Antonios Bayas, MD,
- Frank Hoffmann, MD,
- Ulrich Hofstadt-van Oy, MD,
- Muna Hoshi, MD,
- Jakob Kluge, MD,
- Marius Ringelstein, MD,
- Orhan Aktas, MD,
- Muriel Stoppe, MD,
- Annette Walter, MD,
- Martin S. Weber, MD,
- Ilya Ayzenberg, MD and
- Kerstin Hellwig, MD
- Tania Kümpfel, MD*,
T. Kümpfel has served on advisory boards for Roche Pharma
NONE
T. Kümpfel has received personal compensations/speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma and Biogen as well as grant support from Novartis and Chugai Pharma in the past.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sandra Thiel, PhD*,
NONE
NONE
Bayer Healthcare, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ingrid Meinl, MD,
NONE
NONE
IM received travel expenses from MedDay and Roche Pharma
NONE
NONE
NONE
NONE
NONE
NONE
IM received travel expenses from MedDay and Roche Pharma and compensation from Serono and Roche Pharma
NONE
My husband received grant support from Novartis, Merck and Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My husband received honorarium from Roche, Biogen, Novartis and Bioeq
- Andrea I. Ciplea, PhD,
NONE
NONE
(1) Sanofi-Genzyme, funding for travel (2) Teva, funding for travel (3) Novartis, funding for travel (4) Bayer Healthcare, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antonios Bayas, MD,
(1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Sanofi/Genzyme (6) Roche (7) Alexion (8) Celgene (9) Bayer Vital
NONE
(1) Merck Serono: travel, speaker honoraria (2) Biogen: travel, speaker honoraria (3) Novartis: travel, speaker honoraria (4) TEVA: travel, speaker honoraria (5) Sanofi/Genzyme: travel, speaker honoraria (6) Roche: speaker honoraria (7) Alexion: speaker honoraria (8) Celgene: travel, speaker honoraria (9) Bayer Vital: speaker honoraria
NONE
NONE
NONE
NONE
(1) Merck Serono (2) Biogen (3) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Hoffmann, MD,
Serving on a scientific advisory board for Alexion, Biogen, Novartis, Roche, Sanofi .
NONE
Speaker honoraria and travel fees from Alexion, Bayer, Biogen, CSL Behring, DIAMED Medizintechnik, Grifols, Ipsen, Merck, Novartis, Roche, Sanofi and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from Bayer, Biogen, Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ulrich Hofstadt-van Oy, MD,
NONE
NONE
Honoraria from Alexion (2), Bayer (2), Hormosan (2), Zambon (2) Travel grants from Abbvie (2), Merck (2), Sanofi-Genzyme (2) Reseach grants from Bayer-Schering (2), Novartis (2), Merck (2)
NONE
NONE
NONE
NONE
Roche (2)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Muna Hoshi, MD,
(1) Merck Serono GmbH (2) Biogen GmbH (3) Roche Pharma AG
NONE
(1) Biogen, peaker honoraria (2) Sanofi Genzyme, Speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jakob Kluge, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD,
1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
1. Novartis, funding for speaking at a conference. 2. Ipsen, funding for speaking at a conference. 3. Alexion, funding for speaking at a conference. 4. Roche, funding for speaking at a conference. 5. Bayer Healthcare, funding for travel to a conference. 6. Biogen Idec, funding for travel to a conference. 7. Genzyme, funding for travel to a conference. 8. TEVA, funding for travel to a conference. 9. Merz, funding for travel to a conference. 10. Merck, funding for travel to a conference.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD,
(1) Medimmune Scientific Advisory Board
NONE
(1) Bayer, travel and speaker honoraria (2) Novartis, travel and speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, travel and speaker honoraria (6) Sanofi-Genzyme, travel and speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
(1) Novartis (2) Celgene
NONE
NONE
NONE
(1) Biogen (2) Sanofi-Genzyme (3) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Muriel Stoppe, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annette Walter, MD,
1.) Genzyme 2.) Novartis 3.) Roche
NONE
1.) Genzyme: Honoraria for speaking engagements 2.) Novartis: Honoraria for speaking engagements 3.) Novartis: Costs of congress participation including travel costs and Hotel 4.) Merck: Costs of congress participation including travel costs and Hotel 5.) Bayer: Costs of congress participation including travel costs and Hotel
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1.) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin S. Weber, MD,
Evobrutinib Phase II steering committee
NONE
He received travel funding and/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme.
Academic Editor for PLoS One
NONE
NONE
NONE
NONE
NONE
NONE
NONE
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ilya Ayzenberg, MD and
I took part in advisory boards of comercial pharmaceutrical companies Roche, Alexion, Merck.
NONE
I received speaker honoraria from Roche, Alexion, Santhera companies.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received research grant from Diamed Company.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Hellwig, MD
(1) Novartis (2) Genzyme (3) Teva (4) Merck (5) Roche
NONE
(1) Biogen, funding for travel (2) Novartis, funding for travel (3) Merck, funding for travel (4) Biogen Idec Germany, speaker honoraria (5) Teva, speaker honoraria (6) Sanofi Genzyme, speaker honoraria (7) Novartis, speaker honoraria (8) Bayer Healthcare, speaker honoraria (9) Merck Serono, speaker honoraria (10) Roche, speaker honoraria
NONE
NONE
NONE
NONE
NONE
Honoraria from Biogen, Bayer Healthcare, Teva, Sanofi, Merck and Novartis
NONE
NONE
Biogen, Bayer Healthcare, Teva, Merck, Roche, Sanofi- Genzyme and Novartis
(1) Fund of the Federal Joint Committee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Clinical Neuroimmunology (T.K., I.M.), Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet München, Munich; Department of Neurology (S.T., A.I.C., I.A., K.H.), Katholisches Klinikum, St. Josef Hospital, Ruhr University Bochum; Institute of Clinical Pharmacy and Pharmacotherapy (A.I.C.), Heinrich Heine University Düsseldorf; Department of Neurology (A.B.), University Hospital of Augsburg; Klinik für Neurologie (F.H.), Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle (Saale); Klinik für Neurologie (U.H.-v.O.), Knappschaftskrankenhaus Dortmund Klinikum Westfalen, Dortmund; Marianne-Strauß-Klinik (M.-M.H.), Berg; Department of Neurology (J.K.), Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen; Department of Neurology (M.R., O.A.), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum Düsseldorf; Department of Neurology (M.S.), University of Leipzig; Sektion Neuroimmunologie (A.W.), Klinik für Neurologie, Klinikum Herford; Institute of Neuropathology and Department of Neurology (M.S.W.), University Medical Center, Georg August University Göttingen, Germany.
- Correspondence
Dr. Hellwig zirkuszelt{at}hotmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.